347 related articles for article (PubMed ID: 19619793)
1. Is diffusion-weighted magnetic resonance imaging superior to positron emission tomography with fludeoxyglucose F 18 in imaging non-small cell lung cancer?
Ohba Y; Nomori H; Mori T; Ikeda K; Shibata H; Kobayashi H; Shiraishi S; Katahira K
J Thorac Cardiovasc Surg; 2009 Aug; 138(2):439-45. PubMed ID: 19619793
[TBL] [Abstract][Full Text] [Related]
2. Diffusion-weighted magnetic resonance for pulmonary nodules: 1.5 vs. 3 Tesla.
Ohba Y; Nomori H; Mori T; Shiraishi K; Namimoto T; Katahira K
Asian Cardiovasc Thorac Ann; 2011 Apr; 19(2):108-14. PubMed ID: 21471253
[TBL] [Abstract][Full Text] [Related]
3. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results.
Nomori H; Mori T; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
J Thorac Cardiovasc Surg; 2008 Apr; 135(4):816-22. PubMed ID: 18374761
[TBL] [Abstract][Full Text] [Related]
4. Diffusion-weighted magnetic resonance imaging for diagnosing malignant pulmonary nodules/masses: comparison with positron emission tomography.
Mori T; Nomori H; Ikeda K; Kawanaka K; Shiraishi S; Katahira K; Yamashita Y
J Thorac Oncol; 2008 Apr; 3(4):358-64. PubMed ID: 18379353
[TBL] [Abstract][Full Text] [Related]
5. Preoperative mediastinal and hilar nodal staging with diffusion-weighted magnetic resonance imaging and fluorodeoxyglucose positron emission tomography/computed tomography in patients with non-small-cell lung cancer: which is better?
Wu LM; Xu JR; Gu HY; Hua J; Chen J; Zhang W; Haacke EM; Hu J
J Surg Res; 2012 Nov; 178(1):304-14. PubMed ID: 22541065
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted magnetic resonance imaging in preoperative assessment of non-small cell lung cancer.
Nomori H; Cong Y; Abe M; Sugimura H; Kato Y
J Thorac Cardiovasc Surg; 2015 Apr; 149(4):991-6. PubMed ID: 25686657
[TBL] [Abstract][Full Text] [Related]
7. Prediction of clinical outcome after stereotactic body radiotherapy for non-small cell lung cancer using diffusion-weighted MRI and (18)F-FDG PET.
Iizuka Y; Matsuo Y; Umeoka S; Nakamoto Y; Ueki N; Mizowaki T; Togashi K; Hiraoka M
Eur J Radiol; 2014 Nov; 83(11):2087-92. PubMed ID: 25174774
[TBL] [Abstract][Full Text] [Related]
8. Comparing diffusion-weighted imaging and positron emission tomography for pulmonary nodules measuring from 1 to 3 cm in size.
Nomori H; Cong Y; Sugimura H; Kato Y
Surg Today; 2015 Dec; 45(12):1535-41. PubMed ID: 25673032
[TBL] [Abstract][Full Text] [Related]
9. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
[TBL] [Abstract][Full Text] [Related]
10. Imaging the early response to chemotherapy in advanced lung cancer with diffusion-weighted magnetic resonance imaging compared to fluorine-18 fluorodeoxyglucose positron emission tomography and computed tomography.
Tsuchida T; Morikawa M; Demura Y; Umeda Y; Okazawa H; Kimura H
J Magn Reson Imaging; 2013 Jul; 38(1):80-8. PubMed ID: 23239463
[TBL] [Abstract][Full Text] [Related]
11. 11C-Acetate can be used in place of 18F-fluorodeoxyglucose for positron emission tomography imaging of non-small cell lung cancer with higher sensitivity for well-differentiated adenocarcinoma.
Nomori H; Shibata H; Uno K; Iyama K; Honda Y; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
J Thorac Oncol; 2008 Dec; 3(12):1427-32. PubMed ID: 19057268
[TBL] [Abstract][Full Text] [Related]
12. 11C-acetate for positron emission tomography imaging of clinical stage IA lung adenocarcinoma: comparison with 18F-fluorodeoxyglucose for imaging and evaluation of tumor aggressiveness.
Shibata H; Nomori H; Uno K; Iyama K; Tomiyoshi K; Nakashima R; Sakaguchi K; Goya T; Takanami I; Koizumi K; Suzuki T; Kaji M; Horio H
Ann Nucl Med; 2009 Sep; 23(7):609-16. PubMed ID: 19562438
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
14. Hybrid [¹⁸F]-FDG PET/MRI including non-Gaussian diffusion-weighted imaging (DWI): preliminary results in non-small cell lung cancer (NSCLC).
Heusch P; Köhler J; Wittsack HJ; Heusner TA; Buchbender C; Poeppel TD; Nensa F; Wetter A; Gauler T; Hartung V; Lanzman RS
Eur J Radiol; 2013 Nov; 82(11):2055-60. PubMed ID: 23830904
[TBL] [Abstract][Full Text] [Related]
15. Preliminary comparison of diffusion-weighted MRI and PET/CT in predicting histological type and malignancy of lung cancer.
Liu LP; Zhang XX; Cui LB; Li J; Yang JL; Yang HN; Zhang Y; Zhou Y; Tang X; Qi S; Fang Y; Zhang J; Yin H
Clin Respir J; 2017 Mar; 11(2):151-158. PubMed ID: 25918835
[TBL] [Abstract][Full Text] [Related]
16. Diffusion weighted MRI and 18F-FDG PET/CT in non-small cell lung cancer (NSCLC): does the apparent diffusion coefficient (ADC) correlate with tracer uptake (SUV)?
Regier M; Derlin T; Schwarz D; Laqmani A; Henes FO; Groth M; Buhk JH; Kooijman H; Adam G
Eur J Radiol; 2012 Oct; 81(10):2913-8. PubMed ID: 22197090
[TBL] [Abstract][Full Text] [Related]
17. 2-[Fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography versus whole-body diffusion-weighted MRI for detection of malignant lesions: initial experience.
Komori T; Narabayashi I; Matsumura K; Matsuki M; Akagi H; Ogura Y; Aga F; Adachi I
Ann Nucl Med; 2007 Jun; 21(4):209-15. PubMed ID: 17581719
[TBL] [Abstract][Full Text] [Related]
18. A case of sclerosing hemangioma evaluated with diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose positron emission tomography.
Mori T; Ohba Y; Shiraishi K; Iwatani K; Yoshimoto K; Iyama K
Ann Thorac Cardiovasc Surg; 2010 Aug; 16(4):276-80. PubMed ID: 21057447
[TBL] [Abstract][Full Text] [Related]
19. The maximum standardized uptake values on positron emission tomography of a non-small cell lung cancer predict stage, recurrence, and survival.
Cerfolio RJ; Bryant AS; Ohja B; Bartolucci AA
J Thorac Cardiovasc Surg; 2005 Jul; 130(1):151-9. PubMed ID: 15999056
[TBL] [Abstract][Full Text] [Related]
20. [F-18]Fluorodeoxyglucose positron emission tomography can predict pathological tumor stage and proliferative activity determined by Ki-67 in clinical stage IA lung adenocarcinomas.
Watanabe K; Nomori H; Ohtsuka T; Naruke T; Ebihara A; Orikasa H; Yamazaki K; Uno K; Kobayashi T; Goya T
Jpn J Clin Oncol; 2006 Jul; 36(7):403-9. PubMed ID: 16782729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
